Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ang-3777
2. Snv-003
3. Terevalefim
1. Terevalefim
2. Ang-3777
3. Terevalefim [inn]
4. Terevalefim [usan]
5. Snv-003
6. Gg91uxk2m5
7. 1070881-42-3
8. 500128-99-4
9. 5-((e)-2-thiophen-2-yl-vinyl)-lh-pyrazole
10. 1h-pyrazole, 3-((1e)-2-(2-thienyl)ethenyl)-
11. Bb3
12. Unii-gg91uxk2m5
13. 5-[(e)-2-thiophen-2-ylethenyl]-1h-pyrazole
14. Terevalefim [who-dd]
15. Bb-3
16. Schembl1225335
17. Chembl4650326
18. Schembl10149623
19. Gtpl11997
20. Ang3777
21. Zinc4301780
22. Who 11458
23. 3-[2-(2-thienyl)ethenyl]-1h-pyrazole
24. Hy-137455
25. Cs-0138662
26. (e)-5-(2-(thiophen-2-yl)vinyl)-1h-pyrazole
27. E80357
28. (e)-3-(2-(thiophen-2-yl)vinyl)-1h-pyrazole
| Molecular Weight | 176.24 g/mol |
|---|---|
| Molecular Formula | C9H8N2S |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 2 |
| Exact Mass | 176.04081944 g/mol |
| Monoisotopic Mass | 176.04081944 g/mol |
| Topological Polar Surface Area | 56.9 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 170 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Terevalefim, a small molecule developed by Angion Biomedica Corp., mimics the activity of hepatocyte growth factor (HGF). Through its actions, it activates the c-Met cascade, exhibits c-Met dependence and c-Met receptor activation. As it is able to activate repair pathways, it has been tested in clinical trials for acute kidney injury and in delayed graft function. As of July 2020, Angion has announced a Phase 2 proof-of-concept trial to invesigate terevalefim on preventing and mitigating lung injury in patients with COVID-19 (NCT04459676).
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Terevalefim manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Terevalefim, including repackagers and relabelers. The FDA regulates Terevalefim manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Terevalefim API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Terevalefim supplier is an individual or a company that provides Terevalefim active pharmaceutical ingredient (API) or Terevalefim finished formulations upon request. The Terevalefim suppliers may include Terevalefim API manufacturers, exporters, distributors and traders.
Terevalefim Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Terevalefim GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Terevalefim GMP manufacturer or Terevalefim GMP API supplier for your needs.
A Terevalefim CoA (Certificate of Analysis) is a formal document that attests to Terevalefim's compliance with Terevalefim specifications and serves as a tool for batch-level quality control.
Terevalefim CoA mostly includes findings from lab analyses of a specific batch. For each Terevalefim CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Terevalefim may be tested according to a variety of international standards, such as European Pharmacopoeia (Terevalefim EP), Terevalefim JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Terevalefim USP).
LOOKING FOR A SUPPLIER?
